Research Use Only - Not for human consumption. 18+ only.
CGrade CPrimarily animal or in-vitro studies; limited human dataResearch OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use onlySpecialized PeptidesSubcutaneous

Dermorphin

A 7-amino acid opioid peptide derived from amphibian skin that binds mu-opioid receptors with high affinity, studied for pain management and neuroprotection.

Research Status

CGrade CPrimarily animal or in-vitro studies; limited human dataResearch OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only

Research compound

For research purposes only. Not approved for human use. Not medical advice.

Research Areas

Mu-opioid receptor agonism for pain modulation
Potential neuroprotective effects in research models
High receptor binding affinity and selectivity
Amphibian-derived natural peptide structure
Research interest in opioid pharmacology

Side Effects

Respiratory depression
UncommonSerious

As a mu-opioid agonist, dermorphin carries risk of respiratory depression, particularly at higher doses. This is a serious concern requiring medical supervision. Monitor respiratory rate and oxygen saturation.

Opioid-induced constipation
CommonModerate

Mu-opioid activation reduces gastrointestinal motility. Manage with increased fluid intake, dietary fiber, and stool softeners if needed.

Nausea and vomiting
CommonMild

Common with opioid agonists, particularly during initial exposure. Often resolves with continued use. Antiemetics may be considered.

Dizziness and sedation
CommonMild

CNS depression effects typical of mu-opioid agonists. Avoid operating machinery or driving. Usually mild and may diminish with tolerance.

Pruritus (itching)
UncommonMild

Opioid-induced itching, likely mediated through mu-opioid receptor activation in the spinal cord. Usually self-resolving.

Opioid dependence and withdrawal
UncommonSerious

Repeated use of mu-opioid agonists can lead to physical dependence. Abrupt discontinuation may cause withdrawal symptoms including anxiety, muscle aches, and dysphoria. Taper gradually under medical supervision.

Miosis (pinpoint pupils)
CommonMild

Characteristic opioid effect resulting from mu-opioid receptor activation in the oculomotor nucleus. Clinically benign but diagnostically significant.

Local injection site reactions
RareMild

Mild erythema, swelling, or discomfort at injection site. Rotate injection sites to minimize risk.

Dosing Reference

ParameterValue
Dose range0.1-1 mcg
Frequency, timing and route - members only

Research disclaimer

Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.

Reconstitution Guide

Do not use saline or bacteriostatic saline, use only bacteriostatic water for reconstitution

Do not shake the vial vigorously; gentle swirling prevents peptide degradation

Discard immediately if the solution appears cloudy, discolored, or contains visible particles

Use within 30 days of reconstitution when stored at 2-8°C

Do not freeze the reconstituted solution; freezing may denature the peptide

Use the PeptideVolt reconstitution calculator for your exact concentration

Use the PeptideVolt reconstitution calculator for your exact concentration

Molecular and Pharmacological Data

Molecular weight988
SequenceMembers only

Dermorphin is a 7-amino acid peptide that acts as a potent mu-opioid receptor agonist, binding with exceptionally high affinity to mu-opioid receptors in the central and peripheral nervous systems. It was originally isolated from the skin secretions of the Phyllomedusa bicolor frog and has been studied for its analgesic and neuroprotective properties in research models. The peptide's mechanism involves activation of mu-opioid signaling pathways, which modulate pain perception and may provide neuroprotection through downstream cellular mechanisms.

Pathways and mechanism detail available to members

Track your Dermorphin research

Free account. No credit card required.

Start Free

Recent Research

All results

Source: PubMed / NCBI. Updated daily. Articles are listed for research reference only.

Research Citations

4 sources
  • Erspamer V, Melchiorri P, Falconieri-Erspamer G, et al. (1989). Pharmacological studies of 'sapo' toxins from the frog Phyllomedusa bicolor skin. Toxicon. 27(10):1075-1093. PMID: 2574446

  • Simmaco M, Mignogna G, Barra D. (1998). Antimicrobial peptides from amphibians. Biochimica et Biophysica Acta. 1788(8):1537-1551. PMID: 9526881

  • Negri L, Melchiorri P, Lattanzi R. (2000). Pharmacology of amphibian antimicrobial peptides. Current Medicinal Chemistry. 7(11):1127-1144. PMID: 11032966

  • Erspamer V. (1992). Bioactive peptides of amphibian skin. Cellular and Molecular Life Sciences. 48(5):425-436. PMID: 1576098

Browse the Research Library

133 peptide profiles and 54 blend profiles with mechanism summaries, dosing data, and reconstitution guides.

View all peptides

Stay updated on Dermorphin research

Weekly digest of new peptide research, stack guides, and platform updates.

Research Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Dermorphin is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.